Table 4.

Valve Scores, Re-Reported Echocardiogram Comments, Associated Cabergoline Dose/Duration Parameters and Cardiac Endpoints for 6 Patients Reaching Cardiac Endpoints Where Echocardiogram Images were Available

Patient	Consensus valve score	Cumulative cabergoline at echo (mg)	Duration of cabergoline treatment at echo (days)	Time since first exposure to cabergoline (days)	Approx. age at echo (years)	Time on cabergoline at endpoint (days)	Mean weekly dose (mg)	Endpoint	G.L. comments	S.B. comments
1	0	27	241	241	48	1123	1.28	HF drug	Poor quality scan for right side heart valves
1	2	160	1123	1253	51	1123	1	HF drug
2	2	67	322	2766	35	322	0.69	HF drug
2	2	67	322	3708	37	322	0.69	HF drug
3	0	51.75	777	309	77	1019	2.14	HF drug	Poor quality scan for right side heart valves
4	6	1490	3787	6871	63	3787	0.36	Valve repair	TAVI/prosthesis present. PPM lead through TV	Possible PPM related TR
5	9	266	5306	5782	66	5306	2.85	GP Diagnosis of HF	Aortic valve does not look degenerative	Possible LV dysfunction and secondary MR

Scores: Normal = 0, Mild = 1, Moderate = 2 & Severe = 3. Total possible score 66.

Abbreviations: HF drug, prescription for heart failure drug; MV, mitral valve regurgitation; PPM, permanent pacemaker; TAVI, transcatheter aortic valve implantation; TR, tricuspid valve regurgitation; TV, tricuspid valve.